290 related articles for article (PubMed ID: 32814538)
1. Sodium Glucose Cotransporter-2 Inhibitor Treatment and the Risk of Diabetic Ketoacidosis in Denmark: A Retrospective Cohort Study of Five Years of Use.
Laursen HVB; Røikjer JB; Dal J; Jensen MH
Curr Drug Saf; 2021; 16(1):73-81. PubMed ID: 32814538
[TBL] [Abstract][Full Text] [Related]
2. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
[TBL] [Abstract][Full Text] [Related]
3. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
Eleftheriadou A; Riley D; Zhao SS; Austin P; Hernández G; Lip GYH; Jackson TL; Wilding JPH; Alam U
Diabetologia; 2024 Jul; 67(7):1271-1282. PubMed ID: 38584180
[TBL] [Abstract][Full Text] [Related]
4. Hospitalization of Patients With Diabetes Due to Ketoacidosis Before and After the Initiation of Sodium-Glucose Cotransporter-2 Inhibitors.
Pikielny PR; Lurie TH; Rabia R; Twito O; Rosenblum RH; Yoseph LB
Endocr Pract; 2023 Sep; 29(9):686-691. PubMed ID: 37442436
[TBL] [Abstract][Full Text] [Related]
5. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Musso G; Sircana A; Saba F; Cassader M; Gambino R
PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
[TBL] [Abstract][Full Text] [Related]
6. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study.
Anson M; Zhao SS; Austin P; Ibarburu GH; Malik RA; Alam U
Diabetologia; 2023 Oct; 66(10):1869-1881. PubMed ID: 37505282
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission.
Hamblin PS; Wong R; Ekinci EI; Fourlanos S; Shah S; Jones AR; Hare MJL; Calder GL; Epa DS; George EM; Giri R; Kotowicz MA; Kyi M; Lafontaine N; MacIsaac RJ; Nolan BJ; O'Neal DN; Renouf D; Varadarajan S; Wong J; Xu S; Bach LA
J Clin Endocrinol Metab; 2019 Aug; 104(8):3077-3087. PubMed ID: 30835263
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Clinical Characteristics of Adults Presenting With Sodium-Glucose Cotransporter-2 Inhibitor-Associated Diabetic Ketoacidosis at a Canadian Academic Tertiary Care Hospital.
Clark A; Mohammed AS; Raut A; Moore S; Houlden R; Awad S
Can J Diabetes; 2021 Apr; 45(3):214-219. PubMed ID: 33046401
[TBL] [Abstract][Full Text] [Related]
9. Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.
Stougaard EB; Kristensen PL; Kielgast U; Andersen HU; Hamid Y; Gæde PH; Søndergaard E; Dørflinger GH; Fjeldborg KK; Hansen KW; Thomsen HH; Al-Imar TMJ; Røder M; Sridhar VS; Cherney D; Rossing P; Persson F
Diab Vasc Dis Res; 2022; 19(5):14791641221130043. PubMed ID: 36262089
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
11. A Population-Based Study of SGLT2 Inhibitor-Associated Postoperative Diabetic Ketoacidosis in Patients with Type 2 Diabetes.
Lui DTW; Wu T; Au ICH; Liu X; Fung MMH; Lee CH; Fong CHY; Woo YC; Lang BHH; Tan KCB; Wong CKH
Drug Saf; 2023 Jan; 46(1):53-64. PubMed ID: 36289137
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
13. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors.
Fleming N; Hamblin PS; Story D; Ekinci EI
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32302001
[TBL] [Abstract][Full Text] [Related]
14. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
Horii T; Oikawa Y; Atsuda K; Shimada A
J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
[TBL] [Abstract][Full Text] [Related]
15. Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
Kim YG; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
Diabetes Obes Metab; 2018 Aug; 20(8):1852-1858. PubMed ID: 29569427
[TBL] [Abstract][Full Text] [Related]
16. Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents.
Wang Y; Desai M; Ryan PB; DeFalco FJ; Schuemie MJ; Stang PE; Berlin JA; Yuan Z
Diabetes Res Clin Pract; 2017 Jun; 128():83-90. PubMed ID: 28448895
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.
Edwards K; Li X; Lingvay I
J Clin Endocrinol Metab; 2023 Mar; 108(4):920-930. PubMed ID: 36268825
[TBL] [Abstract][Full Text] [Related]
18. Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital.
Papanastasiou L; Glycofridi S; Gravvanis C; Skarakis N; Papadimitriou I; Kanti G; Kapsali C; Kounadi T
Hormones (Athens); 2021 Jun; 20(2):369-376. PubMed ID: 33151508
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes.
Varshney N; Billups SJ; Saseen JJ; Fixen CW
Ther Adv Drug Saf; 2021; 12():2042098621997703. PubMed ID: 33854754
[TBL] [Abstract][Full Text] [Related]
20. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
Dull RB; Spangler ML; Knezevich EL; Lau BM
J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
